BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Incivek: Additional Phase II data

Additional data from 60 evaluable HCV patients co-infected with HIV-1 from both parts of a 2-part, double-blind, international Phase II trial showed that 74% of patients receiving oral Incivek plus standard of care (SOC; peginterferon alfa-2a and ribavirin) achieved undetectable HCV RNA levels (<25 IU/mL) at week 24 vs. 55% for placebo plus SOC. Additionally, 63% of patients receiving Incivek plus SOC achieved an extended rapid viral response (eRVR), defined as undetectable HCV RNA levels at weeks 4 and 12, vs. 4.5% for placebo plus SOC. Part A of the trial is evaluating Incivek in patients...

Read the full 457 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >